BE2014C016I2 - - Google Patents

Download PDF

Info

Publication number
BE2014C016I2
BE2014C016I2 BE2014C016C BE2014C016C BE2014C016I2 BE 2014C016 I2 BE2014C016 I2 BE 2014C016I2 BE 2014C016 C BE2014C016 C BE 2014C016C BE 2014C016 C BE2014C016 C BE 2014C016C BE 2014C016 I2 BE2014C016 I2 BE 2014C016I2
Authority
BE
Belgium
Application number
BE2014C016C
Other languages
French (fr)
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C016(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of BE2014C016I2 publication Critical patent/BE2014C016I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BE2014C016C 2002-11-15 2014-02-27 BE2014C016I2 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10253282A DE10253282A1 (de) 2002-11-15 2002-11-15 Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung

Publications (1)

Publication Number Publication Date
BE2014C016I2 true BE2014C016I2 (enExample) 2023-03-07

Family

ID=32185709

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C016C BE2014C016I2 (enExample) 2002-11-15 2014-02-27

Country Status (38)

Country Link
EP (2) EP1562603B3 (enExample)
JP (1) JP4317138B2 (enExample)
KR (1) KR101092247B1 (enExample)
CN (3) CN1713914A (enExample)
AR (2) AR041969A1 (enExample)
AT (1) ATE430569T1 (enExample)
AU (1) AU2003285326B2 (enExample)
BE (1) BE2014C016I2 (enExample)
BR (1) BRPI0316264B8 (enExample)
CA (1) CA2506082C (enExample)
CO (1) CO5570670A2 (enExample)
CY (2) CY1110500T1 (enExample)
DE (2) DE10253282A1 (enExample)
DK (1) DK1562603T3 (enExample)
EA (1) EA008665B1 (enExample)
EC (1) ECSP055774A (enExample)
ES (1) ES2326878T7 (enExample)
FR (1) FR14C0049I2 (enExample)
HR (1) HRP20050432B1 (enExample)
HU (1) HUS1400011I1 (enExample)
IL (1) IL167900A (enExample)
LT (1) LTC1562603I2 (enExample)
LU (1) LU92433I2 (enExample)
ME (1) ME00354B (enExample)
MX (1) MXPA05005081A (enExample)
MY (1) MY136034A (enExample)
NL (1) NL300650I2 (enExample)
NO (2) NO334314B1 (enExample)
NZ (1) NZ540661A (enExample)
PE (1) PE20040694A1 (enExample)
PL (1) PL212238B1 (enExample)
PT (1) PT1562603E (enExample)
RS (1) RS51607B (enExample)
SI (1) SI1562603T1 (enExample)
TW (1) TWI343812B (enExample)
UA (1) UA81276C2 (enExample)
WO (1) WO2004045618A2 (enExample)
ZA (1) ZA200502246B (enExample)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
KR20130049840A (ko) * 2004-02-22 2013-05-14 베링거 인겔하임 인터내셔날 게엠베하 벤즈옥사진을 함유하는 호흡기 질환 치료용 약제학적 배합물
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
CA2565243A1 (en) * 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
KR20080036632A (ko) 2005-08-08 2008-04-28 아젠터 디스커버리 리미티드 바이시클로[2.2.1]헵트-7-일아민 유도체 및 이들의 용도
CN101208316B (zh) 2005-08-15 2012-05-09 贝林格尔·英格海姆国际有限公司 制备β-模拟物的方法
US20070088030A1 (en) * 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
TWI396541B (zh) * 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
EP1948186A1 (en) * 2005-11-09 2008-07-30 Boehringer Ingelheim International Gmbh Aerosolformulation for inhalation
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007093608A1 (de) * 2006-02-16 2007-08-23 Boehringer Ingelheim International Gmbh Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
PE20080142A1 (es) * 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
WO2007121920A2 (en) 2006-04-21 2007-11-01 Novartis Ag Purine derivatives for use as adenosin a2a receptor agonists
WO2008017638A1 (de) * 2006-08-07 2008-02-14 Boehringer Ingelheim International Gmbh Enantiomerenreine betaagonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
CA2664378A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as pi3k lipid kinase inhibitors
MX2009004715A (es) 2006-10-30 2009-05-20 Novartis Ag Compuestos heterociclicos como agentes antiinflamatorios.
EP2279777A2 (en) 2007-01-10 2011-02-02 Irm Llc Compounds and compositions as channel activating protease inhibitors
NZ579007A (en) * 2007-01-25 2012-02-24 Boehringer Ingelheim Int Method for producing betamimetics
ES2361595T3 (es) 2007-05-07 2011-06-20 Novartis Ag Compuestos orgánicos.
WO2009074575A2 (en) 2007-12-10 2009-06-18 Novartis Ag Organic compounds
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
US8362064B2 (en) 2008-12-30 2013-01-29 Pulmagen Theraputics (Inflammation) Limited Sulfonamide compounds for the treatment of respiratory disorders
JP2012516345A (ja) 2009-01-29 2012-07-19 ノバルティス アーゲー 星細胞腫治療用置換ベンゾイミダゾール
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CA2770873A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
BR112012003709B1 (pt) 2009-08-17 2021-05-18 Intellikine Llc compostos heterocíclicos e usos dos mesmos
CA2777245A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
MX390695B (es) * 2010-09-21 2025-03-21 Intekrin Therapeutics Inc Composiciones farmaceuticas solidas antidiabeticas
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
KR102115047B1 (ko) 2012-04-03 2020-05-26 노파르티스 아게 티로신 키나제 억제제들을 갖는 조합 제품 및 그의 용도
WO2014056840A1 (en) 2012-10-09 2014-04-17 Boehringer Ingelheim International Gmbh Beta-2-adrenoceptor agonist for the treatment of cough
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
JP2016512835A (ja) 2013-03-15 2016-05-09 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせ及びそれらの使用
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
EA032075B1 (ru) 2014-04-24 2019-04-30 Новартис Аг Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы
CA2945257A1 (en) 2014-04-24 2015-10-29 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US10112926B2 (en) 2014-04-24 2018-10-30 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
EP3174869B1 (en) 2014-07-31 2020-08-19 Novartis AG Combination therapy of a met inhibitor and an egfr inhibitor
CN110062625A (zh) 2016-12-12 2019-07-26 勃林格殷格翰国际有限公司 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法
ES2900283T3 (es) 2016-12-20 2022-03-16 Inke Sa Proceso mejorado para la fabricación de clorhidrato de (R)-6-hidroxi-8-[1-hidroxi-2-[2-(4-metoxifenil)-1,1-dimetiletilaminoetil]-2H-1,4-benzoxazin-3(4H)-ona
CN108997248B (zh) * 2018-08-06 2023-08-01 上海方予健康医药科技有限公司 盐酸奥达特罗晶型b及其制备方法
CN109096218B (zh) * 2018-08-06 2020-10-27 上海方予健康医药科技有限公司 盐酸奥达特罗晶型a及其制备方法
MX2021015133A (es) 2019-06-10 2022-01-24 Novartis Ag Derivado de piridina y pirazina para el tratamiento de la fibrosis quistica, enfermedad pulmonar obstructiva cronica y bronquiectasia.
WO2021038426A1 (en) 2019-08-28 2021-03-04 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
WO2021252577A1 (en) * 2020-06-09 2021-12-16 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
CN1426401A (zh) * 2000-04-27 2003-06-25 贝林格尔英格海姆法玛公司 新的长效倍他米美类药物(betamimetics)其制备方法,及其作为药物组合物的用途

Also Published As

Publication number Publication date
SI1562603T1 (sl) 2009-10-31
CN101735166A (zh) 2010-06-16
PE20040694A1 (es) 2004-11-23
EP2025338A1 (de) 2009-02-18
DE50311502D1 (de) 2009-06-18
MEP53608A (en) 2011-05-10
LTC1562603I2 (lt) 2016-12-12
BRPI0316264B1 (pt) 2019-04-09
JP2006508140A (ja) 2006-03-09
DK1562603T3 (da) 2009-09-07
FR14C0049I2 (fr) 2015-07-24
WO2004045618A2 (de) 2004-06-03
CA2506082A1 (en) 2004-06-03
NZ540661A (en) 2007-12-21
NO2014005I1 (no) 2014-03-10
MXPA05005081A (es) 2005-07-01
HRP20050432A2 (en) 2006-06-30
CO5570670A2 (es) 2005-10-31
PT1562603E (pt) 2009-06-18
CA2506082C (en) 2011-06-21
NO20052883L (no) 2005-06-14
WO2004045618A3 (de) 2004-09-30
ECSP055774A (es) 2005-11-22
ES2326878T3 (es) 2009-10-21
BR0316264A (pt) 2005-10-11
PL375270A1 (en) 2005-11-28
UA81276C2 (en) 2007-12-25
BRPI0316264B8 (pt) 2021-05-25
TW200423943A (en) 2004-11-16
AR087241A2 (es) 2014-03-12
FR14C0049I1 (enExample) 2014-08-08
AU2003285326A1 (en) 2004-06-15
JP4317138B2 (ja) 2009-08-19
RS51607B (sr) 2011-08-31
ZA200502246B (en) 2006-01-25
KR20050075013A (ko) 2005-07-19
CN101817800A (zh) 2010-09-01
MY136034A (en) 2008-07-31
CY1110500T1 (el) 2015-04-29
HUS1400011I1 (hu) 2022-02-28
EA200500715A1 (ru) 2005-12-29
ME00354B (me) 2011-10-10
AU2003285326B2 (en) 2009-06-04
HRP20050432B1 (en) 2012-01-31
EA008665B1 (ru) 2007-06-29
IL167900A (en) 2013-06-27
EP1562603B3 (de) 2014-01-08
EP1562603B1 (de) 2009-05-06
CY2014032I1 (el) 2015-12-09
AR041969A1 (es) 2005-06-01
NL300650I2 (nl) 2017-11-02
TWI343812B (en) 2011-06-21
DE10253282A1 (de) 2004-05-27
KR101092247B1 (ko) 2011-12-12
CY2014032I2 (el) 2015-12-09
EP1562603A2 (de) 2005-08-17
ES2326878T7 (es) 2014-03-11
LU92433I2 (fr) 2014-06-24
ATE430569T1 (de) 2009-05-15
PL212238B1 (pl) 2012-08-31
NO334314B1 (no) 2014-02-03
RS20050361A (sr) 2007-04-10
CN1713914A (zh) 2005-12-28

Similar Documents

Publication Publication Date Title
BE2019C547I2 (enExample)
BE2019C510I2 (enExample)
BE2018C021I2 (enExample)
BE2017C049I2 (enExample)
BE2017C005I2 (enExample)
BE2016C069I2 (enExample)
BE2016C040I2 (enExample)
BE2015C078I2 (enExample)
BE2016C002I2 (enExample)
BE2018C018I2 (enExample)
BE2015C017I2 (enExample)
BE2014C053I2 (enExample)
BE2014C051I2 (enExample)
BE2014C041I2 (enExample)
FR14C0049I1 (enExample)
BE2014C030I2 (enExample)
BE2014C015I2 (enExample)
BE2013C063I2 (enExample)
BE2011C038I2 (enExample)
BE2015C068I2 (enExample)
BE2013C046I2 (enExample)
JP2002273889A5 (enExample)
BR0315835A2 (enExample)
AU2001288935A1 (enExample)
AU2001278584A1 (enExample)